KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EPS (Weighted Average and Diluted): 2016-2024

Historic EPS (Weighted Average and Diluted) for Nektar Therapeutics (NKTR) over the last 9 years, with Dec 2024 value amounting to -$0.58.

  • Nektar Therapeutics' EPS (Weighted Average and Diluted) rose 29.70% to -$1.87 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.63, marking a year-over-year increase of 153.15%. This contributed to the annual value of -$0.58 for FY2024, which is 60.00% up from last year.
  • According to the latest figures from FY2024, Nektar Therapeutics' EPS (Weighted Average and Diluted) is -$0.58, which was up 60.00% from -$1.45 recorded in FY2023.
  • Nektar Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.58 during FY2024, with a 5-year trough of -$2.86 in FY2021.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$1.45 (2023), whereas its average is -$1.33.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first fell by 14.86% in 2021, then surged by 60.00% in 2024.
  • Over the past 5 years, Nektar Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$2.49 in 2020, then decreased by 14.86% to -$2.86 in 2021, then spiked by 31.12% to -$1.97 in 2022, then grew by 26.40% to -$1.45 in 2023, then skyrocketed by 60.00% to -$0.58 in 2024.